EXEL -
Exelixis Inc
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 42.08 0.62 (1.46%) |
-0.01 (-0.01%) |
-0.04 (-0.09%) |
-0.1 (-0.23%) |
--- |
0.62 (1.46%) |
--- |
--- |
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Earnings & Ratios
- Basic EPS:
- 0.68
- Diluted EPS:
- 0.65
- Basic P/E:
- 62.7868
- Diluted P/E:
- 65.6846
- RSI(14) 1m:
- 57.14
- VWAP:
- 42.7
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Oct 31, 2025 11:00
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Oct 28, 2025 17:40
The Ultimate Biotech Stock to Buy With $50 Right Now
Oct 14, 2025 11:30
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight
Oct 13, 2025 17:00
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Sep 30, 2025 08:10
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
Aug 09, 2025 15:40
Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées
Jul 24, 2025 17:41
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 24, 2025 17:41
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Jul 20, 2025 10:30
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Jul 19, 2025 10:09